Ethanol treatment of hepatocellular carcinoma: High potentials of low concentrations

Cancer Biology and Therapy

Volumn 3, Issue 5, 2004, Pages 430-433

  Castaneda, Francisco ^a   Kinne, Rolf K H ^a  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

Author keywords

Apoptosis; Ethanol; Fas receptor; HCC; Necrosis

Indexed keywords

ALCOHOL; DOXORUBICIN; GAMMA INTERFERON; FAS LIGAND; FASLG PROTEIN, HUMAN; MEMBRANE PROTEIN; TOPICAL ANTIINFECTIVE AGENT;

APOPTOSIS; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CELL STRAIN HEPG2; CHEMOEMBOLIZATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; HEPATIC ARTERY; HUMAN; LIVER CELL CARCINOMA; NECROSIS; OUTCOMES RESEARCH; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; DOSE RESPONSE; DRUG EFFECT; LIVER TUMOR; METABOLISM; PATHOLOGY;

ANTI-INFECTIVE AGENTS, LOCAL; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; FAS LIGAND PROTEIN; HUMANS; LIVER NEOPLASMS; MEMBRANE GLYCOPROTEINS;

EID: 21644434806     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.5.806     Document Type: Review

References (56)

1. Teratani T, Ishikawa T, Shiratori Y, Shiina S, Yoshida H, Imamura M, et al. Hepatocellular carcinoma in elderly patients: beneficial therapeutic efficacy using percutaneous ethanol injection therapy. Cancer 2002; 95:816-23.
2. Daniele B, De S, I, Izzo F, Capuano G, Andreana A, Mazzanti R, et al. Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: a Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study. J Clin Gastroenterol 2003; 36:63-7.
3. Castaneda F, Kinne RK. Cytotoxicity of millimolar concentrations of ethanol on HepG2 human tumor cell line compared to normal rat hepatocytes in vitro. J Cancer Res Clin Oncol 2000; 126:503-10.
4. Castaneda F, Kinne RKH. Short exposure to millimolar concentrations of ethanol induces apoptotic cell death in multicellular HepG2 spheroids. J Cancer Res Clin Oncol 2000; 126:305-10.
5. Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32:225-37.
6. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35:519-24.
7. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-50.
8. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MdC, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29:62-7.
9. Little SA, Fong Y. Hepatocellular carcinoma: current surgical management. Semin Oncol 2001; 28:474-86.
10. Herold C, Reck T, Fischler P, Ott R, Radespiel-Troeger M, Ganslmayer M, et al. Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre. Liver 2002; 22:23-8.
11. Arii S, Monden K, Niwano M, Furutani M, Mori A, Mizumoto M, et al. Results of surgical treatment for recurrent hepatocellular carcinoma: comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence. J Hep Bil Pancr Surg 1998; 5:86-92.
12. Nart D, Arikan C, Akyildiz M, Yuce G, Demirpolat G, Zeytunlu M, et al. Hepatocellular carcinoma in liver transplant era: a clinicopathologic analysis. Transpl Proc 2003; 35:2986-90.
13. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362:1907-17.
14. Moriyama M, Hoshida Y, Otsuka M, Nishimura S, Kato N, Goto T, et al. Relevance network between chemosensitivity and transcriptome in human hepatoma cells. Mol Cancer Ther 2003; 2:199-205.
15. Bonin S, Pascolo L, Croce LS, Stanta G, Tiribelli C. Gene expression of ABC proteins in hepatocellular carcinoma, perineoplastic tissue, and liver diseases. Mol Med 2002; 8:318-25.
16. Kato A, Miyazaki M, Ambiru S, Yoshitomi H, Ito H, Nakagawa K, et al. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 2001; 78:110-5.
17. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31:54-8.
18. Dodd GD, 3rd, Soulen MC, Kane RA, Livraghi T, Lees WR, Yamashita Y, et al. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics 2000; 20:9-27.
19. Shiina S, Teratani T, Obi S, Hamamura K, Koike Y, Omata M. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002; 62:64-8.
20. Yu AS, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003; 3:8-24.
21. Ebied OM, Federle MP, Carr BI, Pealer KM, Li W, Amesur N, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003; 97:1042-50.
22. Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002; 13:S211-21.
23. Yamamoto J, Okada S, Shimada K, Okusaka T, Yamasaki S, Ueno H, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001; 34:707-13.
24. Llovet JM, Bruix J. Early diagnosis and treatment of hepatocellular carcinoma. Bailliere's Best Prac Res Clin Gastroenterol 2000; 14:991-1008.
25. Kuriyama H, Okada S, Okusaka T, Ueno H, Ikeda M. Prognostic factors in patients with small hepatocellular carcinoma treated by percutaneous ethanol injection. J Gastroenterol Hepatol 2002; 17:1205-10.
26. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002; 50:123-8.
27. Livraghi T. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. Hepatogastroenterology 2001; 48:20-4.
28. Huo TI, Huang YH, Wu JC, Lee PC, Chang FY, Lee SD. Survival benefit of cirrhotic patients with hepatocellular carcinoma treated by percutaneous ethanol injection as a salvage therapy. Scand J Gastroenterol 2002; 37:350-5.
29. McConkey DJ, Zhivotovsky B, Orrenius S. Apoptosis - molecular mechanisms and biomedical implications. Molelcular Aspects in Medicine 1996; 17:1-110.
30. Schulte-Hermann R, Bursch W, Grasl-Kraupp B. Active cell death (apoptosis) in liver biology and disease. Prog Liver Dis 1995; 13:1-35.
31. Baker RC, Kramer RE. Cytotoxicity of short-chain alcohols. Annu Rev Pharmacol Toxicol 1999; 39:127-50.
32. Adachi M, Ishii H. Role of mitochondria in alcoholic liver injury. Free Radical Biology & Medicine 2002; 32:487-91.
33. McKarns SC, Hansch C, Caldwell WS, Morgan WT, Moore SK, Doolittle DJ. Correlation between hydrophobicity of short-chain aliphatic alcohols and their ability to alter plasma membrane integrity. Fundam Appl Toxicol 1997; 36:62-70.
34. Lieber CS. Alcohol and the liver: metabolism of alcohol and its role in hepatic and extrahepatic diseases. Mount Sinai J Med 2000; 67:84-94.
35. Lieber CS. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998) - a review. Alcohol Clin Exp Res 1999; 23:991-1007.
36. Dai Y, Rashba-Step J, Cederbaum AI. Stable expression of human cytochrome P4502E1 in HepG2 cells: characterization of catalytic activities and production of reactive oxygen intermediates. Biochem 1993; 32:6928-37.
37. Wu D, Cederbaum AI. Ethanol cytotoxicity to a transfected HepG2 cell line expressing human cytochrome P4502E1. J Biol Chem 1996; 271:23914-9.
38. Cederbaum AI, Wu D, Mari M, Bai J. CYP2E1-dependent toxicity and oxidative stress in HepG2 cells. Free Radical Biol Medicine 2001; 31:1539-43.
39. Lieber CS. Alcoholic liver disease: new insights in pathogenesis lead to new treatments. Journal of Hepatology-Supplement 2000; 32:113-28.
40. Diaz GMI, Valles E, Fanelli SL, de Layno AM, Castro GD, Castro JA. Alcohol induction of liver nuclear ethanol and N-nitrosodimethylamine metabolism to reactive metabolites. Teratogen Carcinogen Mutagen 2002; 22:139-45.
41. Ishii H, Kurose I, Kato S. Pathogenesis of alcoholic liver disease with particular emphasis on oxidative stress. J Gastroenterol Hepatol 1997; 12:S272-S82.
42. Gutierrez-Ruiz MC, Quiroz SC, Souza V, Bucio L, Hernandez E, Olivares IP, et al. Cytokines, growth factors, and oxidative stress in HepG2 cells treated with ethanol, acetaldehyde, and LPS. Toxicol 1999; 134:197-207.
43. Clemens DL, Forman A, Jerrells TR, Sorrell MF, Tuma DJ. Relationship between acetaldehyde levels and cell survival in ethanol-metabolizing hepatoma cells. Hepatology 2002; 35:1196-204.
44. Worrall S, de Jersey J, Wilce PA. Comparison of the formation of proteins modified by direct and indirect ethanol metabolites in the liver and blood of rats fed the Lieber- DeCarli liquid diet. Alcohol 2000; 35:164-70.
45. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343:1467-76.
46. Hoek JB, Pastorino JG. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol 2002; 27:63-8.
47. Tapani E, Taavitsainen M, Lindros K, Vehmas T, Lehtonen E. Toxicity of ethanol in low concentrations. Acta Radiol 1996; 37:923-6.
48. Neuman MG, Shear NH, Cameron RG, Katz G, Tiribelli C. Ethanol-induced apoptosis in vitro. Clin Biochem 1999; 32:547-55.
49. Higuchi H, Adachi M, Miura S, Gores GJ, Ishii H. The mitochondrial permeability transition contributes to acute ethanol- induced apoptosis in rat hepatocytes. Hepatology 2001; 34:320-8.
50. Minana JB, Gomez-Cambronero L, Lloret A, Pallardo FV, Del Olmo J, Escudero A, et al. Mitochondrial oxidative stress and CD95 ligand: a dual mechanism for hepatocyte apoptosis in chronic alcoholism. Hepatology 2002; 35:1205-14.
51. Micheau O, Solary E, Hammann A, Dimanche-Boitrel M-T Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 1999; 274:7987-92.
52. Creagh EM, Conroy H, Martin SJ. Caspase-activation pathways in apoptosis and immunity. Immunol Rev 2003; 193:10-21.
53. Castaneda F, Kinne RKH. Apoptosis induced in HepG2 cells by short exposure to millimolar concentrations of ethanol involves the Fas-receptor pathway. J Cancer Res Clin Oncol 2001; 127:418-24.
54. Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radical Biol Medicine 2000; 29:323-33.
55. Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochemie 2002; 84:153-66.
56. Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 1999; 30:413-21.